Literature DB >> 3972443

Mucosal nasopharyngeal immune responses of horses to protein antigens of Streptococcus equi.

J E Galan, J F Timoney.   

Abstract

Mucosal nasopharyngeal immunoglobulin A (IgA) and IgG responses to proteins of Streptococcus equi were studied in horses after the experimental production of strangles. S. equi-specific IgA and IgG titers in nasopharyngeal mucus were much higher in samples from animals 1 to 2 weeks after challenge than in samples from control animals. Although IgA was the major immunoglobulin in nasal mucus, there was more antibody activity associated with IgG as measured by radioimmunoassay. Great differences between the specificities of antibodies in nasal mucus and in serum were detected. IgA and IgG of mucus origin recognized only two major proteins with molecular weights of about 41,000 and 46,000 in acid extracts of S. equi and gave no detectable reaction with culture supernatant proteins. Only one protein of about 62,000 molecular weight was recognized in acid extracts of an equine strain of S. zooepidemicus. In contrast, immunoglobulins in serum recognized a great variety of proteins in culture supernatants and acid extracts of S. equi and S. zooepidemicus which did not include those proteins recognized by immunoglobulins in mucus. These findings provide good evidence for the independence of the local and systemic immune responses of the horse to S. equi. Horses rechallenged shortly after recovery from the first infection were resistant to challenge with an inoculum of S. equi 10 times greater than that to which they were originally susceptible. This resistance appeared to be independent of the levels of bactericidal antibody in serum. We therefore suggest that immunity to S. equi infection is mediated by locally produced nasopharyngeal antibodies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3972443      PMCID: PMC261338          DOI: 10.1128/iai.47.3.623-628.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Protective effect of antibody to parainfluenza type 1 virus.

Authors:  C B Smith; R H Purcell; J A Bellanti; R M Chanock
Journal:  N Engl J Med       Date:  1966-11-24       Impact factor: 91.245

2.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Vaccination of swine for jowl abscesses. Oral administration of group E streptococcus vaccine (live culture-modified).

Authors:  H Engelbrecht; M Dolan
Journal:  Vet Med Small Anim Clin       Date:  1968-09

5.  Vaccination against strangles.

Authors:  H Engelbrecht
Journal:  J Am Vet Med Assoc       Date:  1969-07-15       Impact factor: 1.936

6.  Oral tonsils: an immunoperoxidase study.

Authors:  J B Matthews; M K Basu
Journal:  Int Arch Allergy Appl Immunol       Date:  1982

Review 7.  Mucosal immunology.

Authors:  J Bienenstock; A D Befus
Journal:  Immunology       Date:  1980-10       Impact factor: 7.397

8.  Adherence of Streptococcus equi on tongue, cheek and nasal epithelial cells of ponies.

Authors:  S K Srivastava; D A Barnum
Journal:  Vet Microbiol       Date:  1983-10       Impact factor: 3.293

9.  Intranasal vaccination of dogs with liver avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis.

Authors:  R F Bey; F J Shade; R A Goodnow; R C Johnson
Journal:  Am J Vet Res       Date:  1981-07       Impact factor: 1.156

10.  Rubella immunization of volunteers via the respiratory tract.

Authors:  R Ganguly; P L Ogra; S Regas; R H Waldman
Journal:  Infect Immun       Date:  1973-10       Impact factor: 3.441

View more
  9 in total

1.  Molecular analysis of the M protein of Streptococcus equi and cloning and expression of the M protein gene in Escherichia coli.

Authors:  J E Galán; J F Timoney
Journal:  Infect Immun       Date:  1987-12       Impact factor: 3.441

2.  Cloning and expression in Escherichia coli of a protective antigen of Erysipelothrix rhusiopathiae.

Authors:  J E Galán; J F Timoney
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

3.  Passive transfer of mucosal antibody to Streptococcus equi in the foal.

Authors:  J E Galan; J F Timoney; F W Lengemann
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

4.  Cloning and sequence analysis of a protective M-like protein gene from Streptococcus equi subsp. zooepidemicus.

Authors:  J F Timoney; J Walker; M Zhou; J Ding
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

5.  Immunologic and genetic comparison of Streptococcus equi isolates from the United States and Europe.

Authors:  J E Galán; J F Timoney
Journal:  J Clin Microbiol       Date:  1988-06       Impact factor: 5.948

6.  Streptococcus equi Infections in Horses: Guidelines for Treatment, Control, and Prevention of Strangles-Revised Consensus Statement.

Authors:  A G Boyle; J F Timoney; J R Newton; M T Hines; A S Waller; B R Buchanan
Journal:  J Vet Intern Med       Date:  2018-02-09       Impact factor: 3.333

Review 7.  Comparative models for human nasal infections and immunity.

Authors:  Elisa Casadei; Irene Salinas
Journal:  Dev Comp Immunol       Date:  2018-12-01       Impact factor: 3.636

8.  The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies.

Authors:  Melanie J Lewis; Bettina Wagner; Jenny M Woof
Journal:  Mol Immunol       Date:  2007-07-31       Impact factor: 4.407

9.  A common theme in interaction of bacterial immunoglobulin-binding proteins with immunoglobulins illustrated in the equine system.

Authors:  Melanie J Lewis; Mary Meehan; Peter Owen; Jenny M Woof
Journal:  J Biol Chem       Date:  2008-04-14       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.